Kontafarma China Holdings Limited (HKG:1312)
Hong Kong · Delayed Price · Currency is HKD 0.0310
-0.0010 (-3.13%)
At close: Feb 13, 2026
Kontafarma China Holdings Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 891.73 | 897.52 | 809.11 | 894.06 | 803.27 | 1,009 | |
Revenue Growth (YoY) | 6.55% | 10.93% | -9.50% | 11.30% | -20.40% | 9.55% |
Cost of Revenue | 398.1 | 381.36 | 337.82 | 387.84 | 407.09 | 448.02 |
Gross Profit | 493.63 | 516.16 | 471.29 | 506.22 | 396.18 | 561.11 |
Selling, General & Admin | 536.75 | 524.04 | 542.49 | 558.69 | 456.81 | 506.71 |
Other Operating Expenses | 34.17 | 34.63 | 20.75 | 29.11 | 34.33 | 35.71 |
Operating Expenses | 568.87 | 561.39 | 563.62 | 590.63 | 493.88 | 543.57 |
Operating Income | -75.23 | -45.23 | -92.33 | -84.41 | -97.71 | 17.54 |
Interest Expense | -12.49 | -13.39 | -15.25 | -23.28 | -33.61 | -31.44 |
Interest & Investment Income | 4.86 | 5.82 | 3.5 | 5.18 | 3.31 | 0.82 |
Currency Exchange Gain (Loss) | 23.48 | -7.82 | 5.13 | 4.02 | -2.9 | 1.61 |
Other Non Operating Income (Expenses) | 21.51 | 27.39 | 21.98 | 20.75 | 23.71 | 35.69 |
EBT Excluding Unusual Items | -37.87 | -33.24 | -76.97 | -77.74 | -107.2 | 24.22 |
Impairment of Goodwill | -88.42 | - | - | - | -46.36 | -31.19 |
Gain (Loss) on Sale of Investments | - | - | - | - | 15.24 | -2.02 |
Gain (Loss) on Sale of Assets | -3.8 | -0.03 | 109.77 | -1.9 | 50.23 | -7.02 |
Asset Writedown | -130.25 | -19.94 | -5.54 | - | - | - |
Other Unusual Items | -180.56 | -44.77 | -71.18 | -38.1 | 33.63 | 15.71 |
Pretax Income | -440.9 | -97.98 | -43.92 | -117.74 | -54.47 | -0.3 |
Income Tax Expense | -24.99 | 1.04 | 17.2 | -7.99 | 1.83 | 19.79 |
Earnings From Continuing Operations | -415.91 | -99.02 | -61.12 | -109.74 | -56.3 | -20.09 |
Earnings From Discontinued Operations | - | - | - | 43.33 | 32.67 | -224.77 |
Net Income to Company | -415.91 | -99.02 | -61.12 | -66.41 | -23.63 | -244.86 |
Minority Interest in Earnings | 53.15 | 23.48 | 32.27 | 24.87 | 8.58 | -22.31 |
Net Income | -362.77 | -75.54 | -28.84 | -41.55 | -15.05 | -267.16 |
Net Income to Common | -362.77 | -75.54 | -28.84 | -41.55 | -15.05 | -267.16 |
Shares Outstanding (Basic) | 5,579 | 5,579 | 5,579 | 5,579 | 5,579 | 5,579 |
Shares Outstanding (Diluted) | 5,579 | 5,579 | 5,579 | 5,579 | 5,579 | 5,579 |
EPS (Basic) | -0.07 | -0.01 | -0.01 | -0.01 | -0.00 | -0.05 |
EPS (Diluted) | -0.07 | -0.01 | -0.01 | -0.01 | -0.00 | -0.05 |
Free Cash Flow | 32.13 | 33.41 | 13.2 | -53.84 | 7.88 | 51.03 |
Free Cash Flow Per Share | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.01 |
Gross Margin | 55.36% | 57.51% | 58.25% | 56.62% | 49.32% | 55.60% |
Operating Margin | -8.44% | -5.04% | -11.41% | -9.44% | -12.16% | 1.74% |
Profit Margin | -40.68% | -8.42% | -3.56% | -4.65% | -1.87% | -26.47% |
Free Cash Flow Margin | 3.60% | 3.72% | 1.63% | -6.02% | 0.98% | 5.06% |
EBITDA | -40.22 | -11 | -49.83 | -30.21 | -40 | 81.11 |
EBITDA Margin | -4.51% | -1.23% | -6.16% | -3.38% | -4.98% | 8.04% |
D&A For EBITDA | 35.01 | 34.23 | 42.49 | 54.19 | 57.71 | 63.58 |
EBIT | -75.23 | -45.23 | -92.33 | -84.41 | -97.71 | 17.54 |
EBIT Margin | -8.44% | -5.04% | -11.41% | -9.44% | -12.16% | 1.74% |
Advertising Expenses | - | 427.6 | 419.1 | 428.68 | 313.18 | - |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.